VRTX 10-Q Quarterly Reports

Vertex Pharmaceuticals Inc. reported strong financial results for the third quarter and the first nine months of 2025, demonstrating significant year-over-year growth in product revenues. Total revenues reached $3.1 billion for the quarter, an 11% increase, and $8.8 billion for the nine-month period, up 9%, driven primarily by the sustained demand for their cystic fibrosis (CF) treatments, particularly TRIKAFTA/KAFTRIO, and early contributions from new product launches. The company also highlighted progress in expanding its therapeutic areas beyond CF, with notable advancements in its pipeline for sickle cell disease (SCD), beta-thalassemia (TDT), acute pain, and various kidney and autoimmune diseases. The acquisition of Alpine Immune Sciences in May 2024 continues to be a significant factor, contributing to R&D expenses but also bringing promising candidates like povetacicept into the pipeline. Despite increased operating costs, including R&D and SG&A expenses, driven by commercial investments and pipeline expansion, Vertex maintained robust profitability. The company ended the period with a healthy cash position of $12.0 billion, reflecting strong operating cash flow.

Vertex Pharmaceuticals Inc. reported solid financial results for the second quarter and first half of 2025. Total revenues grew 12% year-over-year to $2.96 billion for the quarter, driven by strong performance in product revenues, which increased by 11% to $2.94 billion. This growth was primarily attributed to continued demand for TRIKAFTA/KAFTRIO and the early contributions from new product launches, including ALYFTREK and JOURNAVX. The company also saw significant growth in its pipeline, with key developments in its Type 1 Diabetes, IgA Nephropathy, and Sickle Cell Disease programs. The company reported a net income of $1.03 billion for the quarter, a substantial turnaround from the net loss of $3.59 billion in the prior year period, which was heavily impacted by the Alpine acquisition's R&D expenses. For the six-month period, net income was $1.68 billion, compared to a net loss of $2.49 billion in the prior year. The company's cash position remains strong, with total cash, cash equivalents, and marketable securities reaching $12.0 billion. Management expects existing liquidity to be sufficient for at least the next twelve months, supported by ongoing operations and a robust product portfolio.

Vertex Pharmaceuticals Inc. reported its first-quarter 2025 financial results, showing a slight increase in total revenues to $2.77 billion, up 3% year-over-year, primarily driven by the sustained performance of TRIKAFTA/KAFTRIO and the initial contributions from its new cystic fibrosis (CF) medicine, ALYFTREK. However, net income saw a significant decline of 41% to $646.3 million, compared to $1.1 billion in the prior year. This decrease was largely influenced by a substantial $379 million intangible asset impairment charge related to the discontinuation of the VX-264 clinical program for type 1 diabetes, and a decrease in acquired in-process research and development (AIPR&D) expenses. The company continues to invest heavily in research and development, with expenses rising 24% year-over-year, reflecting advancements across its diverse pipeline, including treatments for sickle cell disease (SCD), acute pain, and various rare diseases. The launch of JOURNAVX for acute pain has shown early traction with over 20,000 prescriptions written within its first two months. Despite the decrease in net income, Vertex maintains a strong liquidity position with over $11.3 billion in cash, cash equivalents, and marketable securities, supporting ongoing operations and strategic investments.

Vertex Pharmaceuticals Inc. reported solid third-quarter 2024 results, driven by strong performance in its cystic fibrosis (CF) franchise, particularly TRIKAFTA/KAFTRIO, which saw a 14% increase in revenue year-over-year. Overall product revenues grew 12% to $2.8 billion. Despite this revenue growth, the company reported a net loss of $1.45 billion for the first nine months of 2024, primarily due to a significant $4.4 billion acquired in-process research and development (AIPR&D) expense related to the acquisition of Alpine Immune Sciences, Inc. in May 2024. This acquisition, while substantial, brings a promising candidate, povetacicept, for IgA nephropathy. The company is also advancing its pipeline with key near-term launch opportunities including vanzacaftor/tezacaftor/deutivacaftor for CF (PDUFA date January 2, 2025) and suzetrigine for acute pain (PDUFA date January 30, 2025). Furthermore, Vertex continues to invest heavily in research and development, with expenses for the first nine months of 2024 totaling $2.6 billion, reflecting its commitment to its diverse pipeline across various therapeutic areas beyond CF.

Vertex Pharmaceuticals Inc. reported its second-quarter and first-half 2024 financial results, highlighting continued revenue growth driven by its cystic fibrosis (CF) franchise, particularly TRIKAFTA/KAFTRIO. Despite a significant net loss for the period, largely due to a substantial acquired in-process research and development (AIPR&D) charge related to the acquisition of Alpine Immune Sciences, Inc., the company's core product revenue remains strong. Key developments include the acquisition of Alpine, which significantly impacted the quarter's financials but brought povetacicept into the pipeline for kidney diseases. Vertex is also progressing with its non-CF pipeline, with notable advancements in its sickle cell disease therapy, CASGEVY, and upcoming potential launches for vanzacaftor/tezacaftor/deutivacaftor in CF and suzetrigine for acute pain. The company's liquidity remains robust, although cash reserves have decreased due to the Alpine acquisition.

Vertex Pharmaceuticals reported strong financial results for the first quarter of 2024, showcasing significant year-over-year growth in product revenues and a substantial increase in net income. Product revenues rose by 13% to $2.7 billion, driven primarily by the continued strong performance of TRIKAFTA/KAFTRIO in international markets and expanded use in younger age groups in the U.S. This revenue growth, coupled with a strategic decrease in acquired in-process R&D expenses, led to a 46% surge in income from operations and a 57% increase in net income to $1.1 billion. The company's expanding pipeline and recent regulatory approvals, such as CASGEVY for sickle cell disease, highlight its ongoing commitment to innovation and its potential for future growth across multiple therapeutic areas. Financially, Vertex maintains a robust liquidity position with $14.6 billion in cash, cash equivalents, and marketable securities. The company is actively managing its capital, including a substantial share repurchase program and significant investments in R&D. The upcoming acquisition of Alpine Immune Sciences for approximately $4.9 billion underscores Vertex's strategy to bolster its pipeline with promising external assets, particularly in kidney disease. Despite ongoing R&D investments and strategic capital deployment, the company's financial strength and diversified therapeutic focus position it well for continued development and commercial success.

Vertex Pharmaceuticals Inc. reported a solid third quarter and first nine months of 2023, demonstrating continued revenue growth driven by its cystic fibrosis (CF) franchise, particularly TRIKAFTA/KAFTRIO. Total product revenues reached $2.48 billion for the third quarter, an increase of 6% year-over-year, and $7.35 billion for the nine-month period, up 11%. Net income also saw a healthy increase, rising to $1.04 billion for the quarter and $2.65 billion for the nine months. The company is actively investing in its R&D pipeline, with significant increases in R&D and acquired in-process R&D expenses, reflecting progress in key therapeutic areas beyond CF, including sickle cell disease, beta-thalassemia, and various pain and kidney disease programs. Financially, Vertex maintains a strong liquidity position, with cash, cash equivalents, and marketable securities totaling $13.6 billion as of September 30, 2023. The company also continues to execute its capital allocation strategy, evidenced by the $2.7 billion remaining authorization for share repurchases. Upcoming catalysts include regulatory decisions for exa-cel in sickle cell disease and beta-thalassemia, as well as anticipated results from pivotal clinical trials for vanzacaftor/tezacaftor/deutivacaftor in CF and VX-548 in acute pain, positioning the company for potential future growth.

Vertex Pharmaceuticals reported strong financial results for the quarter ending June 30, 2023, with net product revenues increasing by 14% year-over-year to $2.5 billion. This growth was primarily driven by the continued strong performance and international uptake of TRIKAFTA/KAFTRIO, as well as its recent label expansion into younger age groups. Despite a significant increase in operating expenses, largely due to R&D investments in pipeline advancement and preparation for new product launches, net income rose by 13% to $915.7 million. The company is strategically investing in its diverse pipeline, with several key programs in late-stage development, including exa-cel for sickle cell disease and beta thalassemia, vanzacaftor/tezacaftor/deutivacaftor for cystic fibrosis, and VX-548 for acute pain. The positive momentum in the core CF business, coupled with promising developments across multiple therapeutic areas, positions Vertex for continued growth and potential market leadership beyond its established CF franchise. The company maintains a robust liquidity position with $12.6 billion in cash, cash equivalents, and marketable securities, providing ample resources to fund its ongoing operations and strategic initiatives.

Vertex Pharmaceuticals Inc. reported strong financial performance for the first quarter of 2023, with net product revenues reaching $2.37 billion, a 13% increase year-over-year, driven primarily by the continued uptake of TRIKAFTA/KAFTRIO. While overall net income saw a slight decrease to $699.8 million from $762.1 million in the prior year, this was largely influenced by a significant increase in Acquired In-Process Research and Development (AIPR&D) expenses, totaling $347.1 million, up from $2.0 million in Q1 2022, reflecting substantial investments in strategic collaborations and licensing agreements. The company continues to invest heavily in its pipeline, with Research and Development expenses increasing by 24% to $742.6 million. This investment is supporting a broad range of programs targeting serious diseases beyond cystic fibrosis, including sickle cell disease, beta-thalassemia, neuropathic pain, and type 1 diabetes. Vertex also announced a new $3.0 billion share repurchase program, demonstrating a commitment to returning capital to shareholders while maintaining a robust cash position of $11.5 billion in cash, cash equivalents, and marketable securities.

Vertex Pharmaceuticals reported strong financial performance for the nine months ended September 30, 2022, with total revenues reaching $6.63 billion, a 20% increase year-over-year, driven primarily by the continued success of TRIKAFTA/KAFTRIO. Net income for the period grew significantly to $2.50 billion, up 59% from the prior year, reflecting robust revenue growth and effective cost management, although the prior year's results were impacted by a large upfront payment for acquired in-process R&D. The company's balance sheet remains strong, with cash, cash equivalents, and marketable securities totaling $9.77 billion as of September 30, 2022. Vertex also made strategic advancements in its pipeline, notably the acquisition of ViaCyte, Inc., and continued progress in its gene-editing therapies for sickle cell disease and beta thalassemia.

Vertex Pharmaceuticals Inc. reported strong financial performance for the second quarter and first half of 2022. Total revenues grew by 22% year-over-year, reaching $2.196 billion for the quarter and $4.294 billion for the six months ended June 30, 2022. This growth was primarily driven by the continued success of TRIKAFTA/KAFTRIO, both in the U.S. and internationally, as well as its expanded use in younger patient populations. The company also demonstrated robust profitability, with net income increasing significantly to $810.5 million in the second quarter and $1.573 billion for the first half of 2022, compared to $67.0 million and $720.1 million, respectively, in the prior year. This surge in profitability was partly due to a large upfront payment in the prior year to CRISPR, but also reflects strong product revenues and disciplined cost management. The company ended the period with a healthy cash position of $9.3 billion, underscoring its financial strength and ability to fund ongoing research and development initiatives.

Vertex Pharmaceuticals Inc. reported strong financial results for the first quarter of 2022, driven by continued growth in product revenues, particularly from its flagship cystic fibrosis (CF) medicine, TRIKAFTA/KAFTRIO. Total revenues increased by 22% year-over-year to $2,097.5 million, with net product revenues reaching $2,097.5 million. Net income saw a healthy increase of 17% to $762.1 million, translating to a diluted EPS of $2.96. The company's robust cash position strengthened, ending the quarter at $8.2 billion in cash, cash equivalents, and marketable securities. Significant investments in research and development continue, with a focus on advancing a broad pipeline of therapies beyond CF, including promising candidates for sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, and pain.

Vertex Pharmaceuticals reported strong third-quarter 2021 results, driven by significant growth in product revenues, particularly from TRIKAFTA/KAFTRIO in the U.S. and Europe. Total revenues increased by 29% year-over-year to $1.98 billion. While net income saw a substantial increase of 28% to $851.9 million for the quarter, the nine-month period showed a decrease of 25% to $1.57 billion, largely due to a significant upfront payment of $900 million made to CRISPR Therapeutics for the CTX001 collaboration. The company maintains a robust liquidity position with over $6.9 billion in cash, cash equivalents, and marketable securities as of September 30, 2021. Investments in research and development remain high, reflecting Vertex's commitment to advancing its pipeline beyond cystic fibrosis into areas like sickle cell disease, beta thalassemia, and type 1 diabetes. The company continues to expand access to its cystic fibrosis treatments, with ongoing efforts for reimbursement in Canada and priority review for TRIKAFTA in younger age groups. Key pipeline developments include advancing Phase 3 trials for a new CF combination therapy and anticipating regulatory submissions for CTX001 in late 2022. Significant strategic collaborations with CRISPR Therapeutics and Moderna underscore Vertex's focus on both gene editing and mRNA technologies for future therapeutic advancements. Investors should note the substantial R&D investment, particularly the one-time payment to CRISPR, which impacted the year-to-date net income, while the core CF business demonstrates sustained growth.

Vertex Pharmaceuticals Inc. (VRTX) reported its second-quarter and first-half financial results for the period ending June 30, 2021. The company experienced a significant increase in product revenues, driven by strong performance of its cystic fibrosis (CF) treatments, TRIKAFTA/KAFTRIO, particularly in Europe and the U.S. However, net income saw a substantial decrease compared to the prior year, largely due to a $900 million upfront payment made to CRISPR Therapeutics in connection with an amendment to their collaboration agreement for the gene-editing therapy CTX001. Despite the hit to net income from the CRISPR payment, Vertex maintains a strong liquidity position with over $6.7 billion in cash, cash equivalents, and marketable securities. The company continues to invest heavily in research and development, with a particular focus on expanding its CF franchise and advancing its pipeline of cell and gene therapies for other serious diseases like sickle cell disease, type 1 diabetes, and Duchenne muscular dystrophy. Investors should note the significant R&D investment and the ongoing progress in pipeline development alongside the core CF business.

Vertex Pharmaceuticals reported strong revenue growth in the first quarter of 2021, with total revenues increasing by 14% year-over-year to $1.724 billion. This growth was primarily driven by the strong performance of TRIKAFTA/KAFTRIO, particularly its uptake in Europe, and continued solid performance in the U.S. Net income also saw a healthy increase of 8% to $653.1 million, or $2.49 per diluted share. The company continues to invest heavily in research and development, with a focus on expanding its pipeline beyond cystic fibrosis into areas like sickle cell disease, type 1 diabetes, and pain management. Significant upcoming expenditures include a $900 million upfront payment to CRISPR Therapeutics related to the CTX001 gene therapy collaboration. Financially, Vertex maintains a robust liquidity position with $6.9 billion in cash, cash equivalents, and marketable securities. The company also completed its $500 million share repurchase program during the quarter. While the company faces ongoing research and development uncertainties and the potential for significant future expenditures, its strong revenue growth, solid profitability, and healthy balance sheet position it well for continued investment in its pipeline and future growth.

Vertex Pharmaceuticals Inc. (VRTX) reported strong financial performance for the nine months ended September 30, 2020, with total revenues growing by 66% year-over-year to $4.58 billion. This growth was primarily driven by the successful launch and uptake of TRIKAFTA/KAFTRIO, their triple combination regimen for cystic fibrosis (CF), which significantly boosted product revenues. Net income saw a substantial increase of 255% to $2.11 billion, reflecting robust sales growth and improved operational efficiencies. The company continues to invest heavily in research and development, with a strong focus on expanding its CF franchise and diversifying into other therapeutic areas like alpha-1 antitrypsin deficiency, APOL1-mediated kidney diseases, and genetic therapies for sickle cell disease and beta thalassemia. Despite increased R&D and SG&A expenses to support pipeline development and commercialization efforts, Vertex maintains a strong liquidity position with $6.2 billion in cash, cash equivalents, and marketable securities as of September 30, 2020.

Vertex Pharmaceuticals reported robust financial performance for the quarter and six months ended June 30, 2020, driven by a significant surge in product revenues. Total revenues increased by 62% and 69% year-over-year for the respective periods, primarily fueled by the strong launch and uptake of TRIKAFTA. This impressive revenue growth translated into a substantial increase in net income, which more than tripled year-over-year for both the quarter and the six-month period. Despite increased operating expenses, particularly in research and development and sales, general, and administrative functions to support pipeline expansion and commercialization efforts, Vertex maintained strong operational profitability. The company's balance sheet remains strong, with a significant increase in cash, cash equivalents, and marketable securities, providing ample liquidity. Vertex continues to advance its diverse pipeline beyond cystic fibrosis, with promising developments in areas like sickle cell disease, beta-thalassemia, alpha-1 antitrypsin deficiency, and APOL1-mediated kidney diseases. The company is also actively managing its capital structure, including ongoing share repurchase programs and a revolving credit facility, to support its strategic objectives and long-term growth.

Vertex Pharmaceuticals Inc. reported robust financial performance for the first quarter of 2020, driven significantly by the launch and strong uptake of its new cystic fibrosis (CF) therapy, TRIKAFTA, which received U.S. FDA approval in October 2019. Total revenues surged by 76% year-over-year to $1.52 billion, with product revenues nearly doubling to $1.51 billion, primarily due to TRIKAFTA's contribution. This revenue growth outpaced the increase in operating expenses, leading to a substantial 160% rise in income from operations and a remarkable 124% increase in net income to $602.8 million, or $2.29 per diluted share. The company also highlighted its strategic focus on expanding its CF franchise, aiming for treatments covering up to 90% of CF patients, and advancing its pipeline in other serious diseases like AAT deficiency, APOL1-mediated kidney diseases, and pain, as well as exploring genetic therapies. Despite the evolving COVID-19 landscape, Vertex reaffirmed its commitment to maintaining its supply chain and patient access to its medicines, though some R&D activities experienced delays. The company maintained a strong liquidity position with over $4.19 billion in cash, cash equivalents, and marketable securities.

Vertex Pharmaceuticals Inc. reported strong revenue growth for the nine months ended September 30, 2019, with total revenues increasing by 26% to $2.75 billion, primarily driven by a 27% rise in net product revenues to $2.74 billion. This growth was largely attributable to the continued success of their cystic fibrosis (CF) treatments, particularly SYMDEKO/SYMKEVI, which saw a 129% increase in revenue for the nine-month period. The company also announced a significant milestone with the FDA approval of TRIKAFTA in October 2019, a triple combination regimen expected to expand treatment options for a broader CF patient population and contribute to future revenue growth. While revenues are strong, operating costs and expenses also increased significantly by 26% to $2.1 billion for the nine-month period. This rise was mainly due to substantial upfront payments for collaboration agreements with CRISPR and Kymera Therapeutics, totaling $261.6 million in R&D expenses, and costs associated with the acquisition of Exonics Therapeutics. Despite increased expenses, the company's net income attributable to Vertex for the nine months increased by 9% to $593.6 million, demonstrating robust underlying profitability. Vertex also maintains a strong liquidity position with $4.0 billion in cash, cash equivalents, and marketable securities as of September 30, 2019.

Vertex Pharmaceuticals Inc. reported robust financial performance for the period ending June 30, 2019, with total revenues reaching $941.3 million for the quarter and $1.8 billion for the six-month period, representing significant year-over-year growth. This strong revenue performance was primarily driven by a substantial increase in net product revenues, particularly from the SYMDEKO/SYMKEVI drug. The company also demonstrated solid profitability, with net income attributable to Vertex rising to $267.4 million for the quarter and $536.1 million for the six-month period. Research and development expenses saw an increase, reflecting ongoing investments in pipeline expansion, including significant upfront payments for new collaborations and the acquisition of Exonics Therapeutics. Management anticipates continued revenue growth and has substantial liquidity, with cash, cash equivalents, and marketable securities totaling $3.95 billion, positioning the company well for future operational needs and strategic initiatives.

Vertex Pharmaceuticals Inc. reported strong financial results for the first quarter ended March 31, 2019. Total revenues surged by 34% year-over-year to $858.4 million, primarily driven by a significant 34% increase in net product revenues to $857.3 million. This growth was largely attributable to the strong performance of SYMDEKO/SYMKEVI, which saw a remarkable 839% increase in revenue. Net income attributable to Vertex also grew substantially by 28% to $268.6 million, translating to a diluted earnings per share of $1.03. The company's robust revenue growth outpaced the increase in operating costs and expenses, which rose by 14%. Vertex continues to invest heavily in research and development, with expenses increasing by 9% to $339.5 million, reflecting its commitment to expanding its pipeline. The company's balance sheet remains strong, with cash, cash equivalents, and marketable securities totaling $3.5 billion, providing ample liquidity for future operations and strategic initiatives.

Vertex Pharmaceuticals Inc. reported a strong financial performance for the nine months ended September 30, 2018, with net income attributable to Vertex of $546.4 million, a significant increase from $162.8 million in the same period of 2017. This growth was primarily driven by a substantial increase in product revenues, particularly from their cystic fibrosis (CF) therapies, which rose by 41% to $2.17 billion. The launch of SYMDEKO and continued growth of KALYDECO were key contributors, partially offset by a decline in ORKAMBI revenues as patients transitioned to newer treatments. The company also benefited from a significant decrease in operating costs and expenses, largely due to the absence of one-time charges that impacted the prior year's results, such as the intangible asset impairment and acquisition costs. The company's financial position strengthened, with cash, cash equivalents, and marketable securities increasing to $3.1 billion, and working capital growing to $2.7 billion. Vertex continues to invest heavily in research and development, with a robust pipeline focused on advancing next-generation CFTR corrector compounds and exploring other therapeutic areas. The company is well-positioned to fund its ongoing operations and R&D initiatives, with management expecting current cash flows and existing resources to be sufficient for at least the next twelve months.

Vertex Pharmaceuticals Inc. reported strong financial performance for the second quarter and first half of 2018, driven primarily by significant growth in cystic fibrosis (CF) product revenues. Total revenues increased by 38% in the quarter and 11% year-to-date, reaching $752.2 million and $1.39 billion, respectively. Net income attributable to Vertex surged to $207.4 million ($0.80/diluted share) in Q2 2018, a substantial increase from $18.0 million ($0.07/diluted share) in Q2 2017. For the first half of 2018, net income was $417.6 million ($1.61/diluted share), up from $265.8 million ($1.06/diluted share) in the prior year. This growth was propelled by the successful launch and uptake of SYMDEKO, along with continued strong performance from KALYDECO. While ORKAMBI sales saw a slight decrease due to patients switching to SYMDEKO, the overall CF franchise demonstrated robust expansion. The company also highlighted the positive impact of adopting new revenue recognition standards (ASC 606) and changes in accounting for equity investments, which contributed to increased reported revenues and other income respectively.

Vertex Pharmaceuticals Inc. reported total revenues of $640.8 million for the three months ended March 31, 2018, a decrease of 10% compared to $714.7 million in the same period of 2017. This decline was primarily driven by a significant drop in collaborative revenues, largely due to a one-time $230 million upfront payment from Merck KGaA recognized in the prior year's quarter. However, product revenues showed strong growth, increasing by 33% to $637.7 million, driven by the continued success of KALYDECO and ORKAMBI, and the recent launch of SYMDEKO. Net income attributable to Vertex decreased by 15% to $210.3 million ($0.81 per diluted share) from $247.8 million ($0.99 per diluted share) in the prior year. This decrease was influenced by the aforementioned revenue drop and increased operating expenses, particularly in research and development and cost of sales. Despite these challenges, the company's cash position remains robust, with cash, cash equivalents, and marketable securities totaling $2.5 billion, an increase of $388 million from the previous quarter. The company's strategic investments, notably in CRISPR Therapeutics, also saw a significant increase in fair value, contributing to other income. Vertex is advancing its next-generation CFTR corrector compounds, VX-659 and VX-445, in Phase 3 clinical trials, which have the potential to treat a broader patient population. The company also highlighted ongoing label expansion efforts for its existing CF medicines. Despite the revenue dip primarily from a one-time event, the core business of product sales is growing, and the company maintains a strong financial position to fund its extensive R&D pipeline.

Vertex Pharmaceuticals Inc. reported a net loss attributable to Vertex of $103.0 million for the third quarter of 2017, compared to a net loss of $38.8 million in the prior year's third quarter. This widened loss was primarily driven by a significant $255.3 million intangible asset impairment charge related to Parion's pulmonary ENaC platform and a $160.0 million acquisition payment for VX-561, which were not present in the prior year period. Despite the net loss, total revenues saw a substantial increase of 40% year-over-year, reaching $578.2 million, propelled by strong growth in product revenues from ORKAMBI and KALYDECO, which increased by 34% and 22% respectively. For the nine months ended September 30, 2017, Vertex reported a net income of $162.8 million, a significant improvement from a net loss of $145.0 million in the same period last year. This turnaround was aided by continued growth in product revenues and a substantial $231.7 million in collaborative revenue recognized from the Merck KGaA agreement. However, the operating costs and expenses also increased considerably, largely due to the aforementioned impairment charge and acquisition payment. Investors should note the significant R&D investments continuing, especially in next-generation CFTR corrector compounds, which are crucial for future growth, alongside the ongoing regulatory review for tezacaftor in combination with ivacaftor.

Vertex Pharmaceuticals reported a return to profitability in the six months ended June 30, 2017, with net income attributable to Vertex of $265.8 million, a significant improvement from a net loss of $106.2 million in the same period of 2016. This turnaround was largely driven by a substantial increase in total revenues, which rose to $1.26 billion from $830 million, primarily boosted by a $230 million upfront payment from Merck KGaA for an oncology collaboration and increased product revenues from its key cystic fibrosis (CF) drugs, ORKAMBI and KALYDECO. The company continues to invest heavily in research and development, particularly in its next-generation CFTR corrector compounds for CF, with promising early-stage clinical trial data. The acquisition of CTP-656 from Concert Pharmaceuticals for $160 million highlights Vertex's commitment to expanding its CF pipeline. While the company faces ongoing challenges in securing ex-U.S. reimbursement for ORKAMBI, its overall financial performance shows a positive trajectory, supported by strong product sales and strategic collaborations.

Vertex Pharmaceuticals Inc. reported a significant turnaround in its financial performance for the first quarter of 2017 compared to the same period in 2016. The company achieved a net income of $247.8 million, a substantial improvement from a net loss of $41.6 million in Q1 2016. This turnaround was driven by a nearly 80% increase in total revenues, reaching $714.7 million, largely fueled by a substantial $232.5 million in collaborative revenues from a new agreement with Merck KGaA, alongside a 22% growth in net product revenues from its key cystic fibrosis (CF) drugs, ORKAMBI and KALYDECO. Key drivers for the revenue growth include strong product sales from ORKAMBI, which increased by 32%, and KALYDECO, up 9%. The company also announced positive Phase 3 clinical trial results for tezacaftor in combination with ivacaftor, paving the way for potential regulatory submissions. Despite increased operating expenses, primarily in research and development and restructuring, Vertex demonstrated robust profitability. The company maintained a healthy liquidity position with over $1.4 billion in cash, cash equivalents, and marketable securities, positioning it well to fund ongoing operations and development programs, including a pending acquisition of CTP-656.

Vertex Pharmaceuticals Inc. reported a net loss of $38.8 million for the third quarter of 2016, a significant improvement from a net loss of $95.1 million in the same period last year. This improvement was driven by a substantial increase in total revenues, which grew by 34% to $413.8 million, primarily fueled by strong growth in product revenues. ORKAMBI and KALYDECO were the key drivers, with ORKAMBI revenue increasing by 79% to $234.0 million and KALYDECO revenue growing by 6% to $175.6 million. Despite the revenue growth, operating costs and expenses also increased, by 14% to $432.5 million, largely due to higher research and development and cost of product revenues. The company continues to invest heavily in its pipeline, particularly in cystic fibrosis therapies. Looking ahead, Vertex anticipates continued revenue growth from its approved products and progress in its extensive clinical development programs, aiming to solidify its position in the CF market and explore new therapeutic areas.

Vertex Pharmaceuticals Inc. reported significant revenue growth in its second quarter and first half of 2016, driven primarily by strong sales of its cystic fibrosis (CF) therapies, ORKAMBI and KALYDECO. ORKAMBI, approved in mid-2015, is showing substantial traction, with revenues partially offset by patient discontinuations, though the company expects continued growth. KALYDECO also contributed to increased revenue through label expansions and broader patient access. Despite revenue growth, the company incurred net losses attributable to Vertex in both periods. Research and development expenses saw a notable increase, reflecting ongoing clinical trials and investments in future drug candidates across CF and other therapeutic areas like oncology and pain. The company also made a significant investment in CRISPR Therapeutics, underscoring its commitment to innovative technologies. Vertex maintains a healthy liquidity position with over $1 billion in cash, cash equivalents, and marketable securities, which is expected to fund operations for at least the next twelve months.

Vertex Pharmaceuticals Inc. reported a significant increase in total revenues for the first quarter of 2016, reaching $398.1 million, a substantial jump from $138.5 million in the prior year period. This growth was primarily driven by the strong performance of ORKAMBI, which was approved in mid-2015, and continued growth in KALYDECO sales. Despite the revenue surge, the company reported a net loss attributable to Vertex of $41.6 million for the quarter, an improvement from the $198.6 million net loss in Q1 2015. The company's research and development expenses increased to $255.9 million, reflecting ongoing investment in its pipeline, particularly in cystic fibrosis therapies. Vertex's balance sheet remains robust, with $1.03 billion in cash, cash equivalents, and marketable securities as of March 31, 2016. Management expects current liquidity and anticipated cash flows from product sales to be sufficient for at least the next twelve months. The company continues to focus on advancing its key drug candidates, especially in cystic fibrosis, and managing its operational expenses while investing in future growth opportunities.

Vertex Pharmaceuticals reported a significant increase in total revenues for the nine months ended September 30, 2015, driven by the launch of ORKAMBI and strong performance from KALYDECO. While the company continues to incur substantial research and development expenses, particularly in its core cystic fibrosis program, the net loss attributable to Vertex narrowed significantly compared to the same period in the prior year. The company also made strategic advancements, including a significant collaboration with CRISPR Therapeutics for gene editing technologies and progress in its clinical trials for various CFTR modulator candidates. Key financial highlights include a substantial rise in product revenues, largely due to the initial sales of ORKAMBI post-FDA approval in July 2015. Despite increased operating costs, particularly in R&D and SG&A, the company's revenue growth outpaced expense growth, leading to a reduced net loss. Vertex maintains a strong liquidity position with over $1 billion in cash, cash equivalents, and marketable securities, providing a solid foundation for its ongoing development and commercialization efforts.

Vertex Pharmaceuticals Inc. reported its financial results for the period ending June 30, 2015. The company experienced a significant increase in product revenues, primarily driven by KALYDECO, but this was offset by decreases in royalty and collaborative revenues. Despite revenue growth, Vertex continues to operate at a net loss, which widened slightly compared to the prior year period due to increased operating costs and expenses, particularly in sales, general, and administrative functions. A key development during the period was the significant investment in a collaboration with Parion Sciences for the development of ENaC inhibitors, which also led to a substantial increase in intangible assets and goodwill on the balance sheet. The company also achieved a significant milestone with the FDA approval of ORKAMBI (lumacaftor in combination with ivacaftor) in July 2015, shortly after the reporting period. While this is a crucial step towards future revenue generation, the company anticipates significant reimbursement discussions in ex-U.S. markets, suggesting that ORKAMBI's full revenue potential may take time to materialize globally. Overall, Vertex is investing heavily in its research and development pipeline, particularly in cystic fibrosis, while managing its financial resources to support ongoing operations and future commercialization efforts.

Vertex Pharmaceuticals Inc. reported a net loss of $198.6 million for the first quarter of 2015, an improvement from the $232.5 million net loss in the same period last year. This reduction in loss was driven by a 17% increase in total revenues, primarily due to a 26% surge in product revenues, largely from KALYDECO (ivacaftor). While R&D expenses decreased year-over-year, Sales, General & Administrative (SG&A) expenses saw an increase, reflecting preparations for the potential launch of ORKAMBI (lumacaftor in combination with ivacaftor). The company's cash position remains strong, with $1.18 billion in cash, cash equivalents, and marketable securities as of March 31, 2015. The key focus for investors remains the anticipated approval and commercialization of ORKAMBI, with a PDUFA date of July 5, 2015, for the U.S. market. The company expects ORKAMBI to be a significant driver of future revenue growth. Management believes existing liquidity is sufficient for the next twelve months, but future capital needs will depend on the success of KALYDECO, ORKAMBI, and other pipeline developments.

Vertex Pharmaceuticals Inc. reported a net loss attributable to Vertex of $170.1 million for the third quarter of 2014, compared to a net loss of $124.1 million in the same period of 2013. This widening loss was driven by a significant decrease in total revenues, down 19% to $179.0 million, primarily due to a sharp decline in INCIVEK product revenues (-88%) and a substantial drop in royalty revenues (-69%). These decreases were partially offset by increased KALYDECO net product revenues (+25%) and a surge in collaborative revenues, largely from an upfront payment related to an out-license agreement. Despite lower overall revenues, total operating costs and expenses decreased by 7% due to reduced R&D and SG&A spending, though restructuring expenses significantly increased (+239%). For the nine months ended September 30, 2014, the net loss widened to $561.9 million from $489.3 million in the prior year. Total revenues saw a substantial 49% decrease, primarily driven by the continued decline of INCIVEK sales. Operating costs and expenses also decreased significantly by 33%, largely due to the absence of a large intangible asset impairment charge recorded in the prior year and reduced R&D, SG&A, and cost of product revenues. The company ended the period with $1.48 billion in cash, cash equivalents, and marketable securities, providing a substantial liquidity buffer as it advances its key development programs, notably the combination of lumacaftor and ivacaftor for cystic fibrosis.

Vertex Pharmaceuticals Inc. reported a significant net loss for the three and six months ended June 30, 2014, primarily driven by high research and development expenses. Total revenues declined substantially year-over-year, largely due to a sharp decrease in INCIVEK product revenues, though this was partially offset by growth in KALYDECO net product revenues. The company has made progress on its key pipeline drug, lumacaftor in combination with ivacaftor, with positive Phase 3 trial data and plans to submit for regulatory approval. Despite the current net loss, Vertex Pharmaceuticals maintains a substantial cash position, bolstered by a recent $300 million term loan, which is expected to fund operations for at least the next twelve months. Investor focus should be on the upcoming regulatory submission for lumacaftor/ivacaftor, which represents the company's primary growth driver. The company's ability to navigate the approval process and subsequent market penetration will be critical for future profitability. Continued growth in KALYDECO sales and effective management of R&D spending are also key areas to monitor.

Vertex Pharmaceuticals Inc. reported a significant decrease in total revenues for the first quarter of 2014, down 64% to $118.5 million compared to $328.4 million in the prior year's quarter. This decline was primarily driven by a substantial drop in INCIVEK product revenues, which fell by 98% to $3.9 million, while KALYDECO revenues showed strong growth, increasing 61% to $99.5 million. Despite a reduction in operating costs and expenses, largely due to a significant intangible asset impairment charge in the prior year, the company continued to incur substantial net losses, with a net loss attributable to Vertex of $232.5 million ($1.00 per diluted share) in the current quarter, compared to a loss of $308.0 million ($1.43 per diluted share) in the first quarter of 2013. The company is heavily investing in research and development, particularly for cystic fibrosis treatments, with R&D expenses increasing by 10% to $239.0 million. Financially, Vertex ended the quarter with approximately $1.32 billion in cash, cash equivalents, and marketable securities, indicating sufficient liquidity for at least the next twelve months. However, the company's reliance on KALYDECO sales and uncertain reimbursement discussions in international markets for future revenue growth remain key considerations for investors. The company's strategic shift away from Hepatitis C (HCV) treatments, as evidenced by the intangible asset impairment charges and reduced focus on INCIVEK, highlights a pivot towards its core cystic fibrosis pipeline.

Vertex Pharmaceuticals Inc. (VRTX) reported a significant net loss of $124.1 million for the third quarter of 2013, a substantial increase from the $57.5 million loss in the same period last year. This widened loss is primarily driven by a steep decline in product revenues, largely due to the diminishing sales of INCIVEK, its hepatitis C treatment. While KALYDECO, a cystic fibrosis drug, saw increased revenues, it was not enough to offset the decline in INCIVEK sales. The company also incurred significant research and development expenses, alongside restructuring charges related to workforce reductions and asset impairments, notably a $412.9 million charge for VX-222. Despite the widening net loss and declining INCIVEK revenue, Vertex Pharmaceuticals maintains a strong liquidity position with $1.4 billion in cash, cash equivalents, and marketable securities as of September 30, 2013. The company is strategically focusing its investments on its cystic fibrosis pipeline, particularly on expanding KALYDECO's label and advancing the combination of ivacaftor and lumacaftor, and on developing all-oral, interferon-free regimens for HCV. Investors should monitor the progress of these key development programs and the impact of the ongoing strategic restructuring on future financial performance.

Vertex Pharmaceuticals reported a net loss attributable to Vertex of $57.2 million ($0.26 per diluted share) for the second quarter of 2013, an improvement from the $64.9 million loss ($0.31 per diluted share) in the same period last year. This improvement was driven by a significant decrease in product revenues, primarily due to declining INCIVEK sales, offset by increased KALYDECO revenues and higher royalty income from INCIVO. Despite the revenue decline, the company managed operating expenses, leading to a narrower loss. However, the first half of 2013 saw a substantial net loss of $365.2 million, largely impacted by a significant $412.9 million intangible asset impairment charge related to the VX-222 drug candidate. The company continues to invest heavily in research and development, particularly in cystic fibrosis and Hepatitis C, with several key drug candidates in late-stage development. Management expects current cash, cash equivalents, and marketable securities to be sufficient for at least the next twelve months.

Vertex Pharmaceuticals Inc. reported a significant net loss of $308.0 million for the first quarter of 2013, a sharp contrast to the $91.6 million net income in the same period of 2012. This loss was primarily driven by a substantial $412.9 million intangible asset impairment charge related to their VX-222 asset. Total revenues also declined by 25% year-over-year to $328.4 million, largely due to a 29% decrease in product revenues, with INCIVEK sales showing a notable drop, though partially offset by growth in KALYDECO. Despite the reported net loss and revenue decline, the company maintains a strong liquidity position with $1.2 billion in cash, cash equivalents, and marketable securities as of March 31, 2013. Investment in research and development increased by 11% to $218.1 million, underscoring Vertex's commitment to its pipeline, particularly in Cystic Fibrosis and Hepatitis C. The company is strategically focusing on KALYDECO's growth and advancing its pipeline candidates to mitigate the expected continued decline in INCIVEK revenues.

Vertex Pharmaceuticals Inc. reported a net loss attributable to Vertex of $57.5 million for the third quarter of 2012, a significant change from the $221.1 million net income reported in the same period of the prior year. This shift was primarily driven by a substantial decrease in collaborative revenues, largely due to the absence of milestone payments received in the prior year, and a decline in INCIVEK product revenues. Total revenues for the quarter fell to $336.0 million from $659.2 million year-over-year. Despite the revenue decrease, operating costs and expenses were reduced, largely due to the absence of a significant intangible asset impairment charge recorded in the prior year. For the nine-month period ended September 30, 2012, Vertex reported a net loss attributable to Vertex of $30.9 million, an improvement compared to a net loss of $129.1 million in the same period of 2011. This improvement was driven by a significant increase in product revenues, more than doubling to $1.05 billion, primarily from the launch of KALYDECO and continued sales of INCIVEK, alongside increased royalty revenues. However, collaborative revenues decreased substantially. The company ended the period with $1.3 billion in cash, cash equivalents, and marketable securities, providing a strong liquidity position to fund ongoing research and development and commercialization efforts.

This filing is an amendment to Vertex Pharmaceuticals Inc.'s Quarterly Report on Form 10-Q for the period ended June 30, 2008. The amendment's primary purpose is to refile an exhibit with fewer redactions, for which the company had previously requested confidential treatment. Importantly, this amendment does not update the financial or operational disclosures beyond the original filing date of August 11, 2008. Therefore, the information presented reflects the company's status and financial position as of that earlier date, not as of September 7, 2012, when this amendment was filed. Investors reviewing this document should be aware that it is not a current report on the company's performance in 2012. It serves as a historical record and an update to a specific exhibit from a filing made over four years prior to the current filing date. For up-to-date financial and operational information, investors should consult Vertex Pharmaceuticals' more recent filings.

Vertex Pharmaceuticals Incorporated (VRTX) reported its financial results for the quarter and six months ended June 30, 2012. The company experienced a significant increase in total revenues, primarily driven by the strong performance of its key products INCIVEK and KALYDECO, which launched in May 2011 and January 2012, respectively. Despite the revenue growth, Vertex reported a net loss attributable to Vertex of $64.9 million for the quarter, compared to a net loss of $174.1 million in the prior year period. This was largely due to a substantial inventory write-down for INCIVEK ($78.0 million) and an increase in the fair value of contingent liabilities related to the Alios collaboration ($56.2 million). For the six-month period, Vertex reported a net income of $26.7 million, a significant improvement from the net loss of $350.2 million in the comparable period of 2011. The company's liquidity remains strong, with $1.2 billion in cash, cash equivalents, and marketable securities as of June 30, 2012, providing sufficient resources to fund operations and ongoing research and development efforts.

Vertex Pharmaceuticals Inc. reported a significant turnaround in its financial performance for the quarter ended March 31, 2012, compared to the same period in the prior year. The company transitioned from a net loss of $176.1 million in Q1 2011 to a net income of $91.6 million in Q1 2012. This dramatic improvement was driven by the successful commercial launch and sales of its key products, INCIVEK and KALYDECO, which generated substantial product revenues. Additionally, royalty revenues from collaboration partners contributed positively to the top line. Despite increased operating expenses, largely due to higher research and development, sales, general, and administrative costs associated with commercialization efforts, Vertex achieved profitability. The company's strong cash position, bolstered by product sales, provides a solid foundation for continued investment in its robust pipeline of drug candidates targeting serious diseases like Hepatitis C and Cystic Fibrosis. Investors should monitor the ongoing clinical development and potential regulatory approvals of these pipeline assets, as well as the competitive landscape for its existing products.

This filing is an amendment (No. 2) to Vertex Pharmaceuticals Inc.'s Quarterly Report on Form 10-Q for the period ended June 30, 2011. The primary purpose of this amendment is to refile certain exhibits with fewer redactions, specifically related to agreements. It's important to note that this amendment does not update the financial or operational disclosures beyond the original filing date of August 9, 2011, and continues to speak as of that date. Investors should recognize that the core financial and business information presented in this report reflects the company's status as of mid-2011. The focus of the amendment is on the disclosure of contractual arrangements, particularly highlighting a License and Collaboration Agreement with Alios BioPharma, Inc. dated June 13, 2011, and various amendments to its significant Research, Development, and Commercialization Agreement with the Cystic Fibrosis Foundation Therapeutics Incorporated.

Vertex Pharmaceuticals Incorporated (VRTX) reported strong financial results for the third quarter of 2011, driven by the successful launch and sales of its hepatitis C drug, INCIVEK™. The company generated significant product revenues and achieved profitability for the quarter, a notable improvement from previous periods. This performance was further bolstered by milestone payments from its collaboration with Janssen Pharmaceutica, N.V. regarding INCIVO. Beyond INCIVEK's commercial success, Vertex is advancing its pipeline with regulatory submissions for KALYDECO™ (VX-770) for cystic fibrosis. The company also recorded an intangible asset impairment charge related to VX-759, a backup drug candidate, due to the advancement of its lead candidate, VX-222. Despite increased operating expenses related to commercialization and R&D investments, Vertex ended the quarter with a healthy cash position and anticipates continued revenue growth from its key products.

Vertex Pharmaceuticals Inc. (VRTX) has filed an amendment to its Form 10-Q for the quarter ended June 30, 2011. This amendment primarily serves to file two exhibits with fewer redactions for which confidential treatment was previously requested, and to include updated officer certifications. The company states that this amendment does not update the disclosures to reflect events occurring after the original filing date of August 9, 2011. Investors should note that the core financial and operational information remains as previously reported, with the amendment focused on the public disclosure of previously confidential agreement details.

Vertex Pharmaceuticals reported its second-quarter 2011 financial results, marked by the significant event of beginning to market its hepatitis C drug, INCIVEK (telaprevir), in the United States. This led to the generation of $74.5 million in product revenue during the quarter. While the company continues to invest heavily in research and development, particularly for its cystic fibrosis program with VX-770 nearing regulatory submission, the INCIVEK launch represents a pivotal moment for revenue generation and future profitability. The company's financial performance in the quarter showed a reduced net loss attributable to Vertex compared to the prior year, largely driven by the new product revenue and a decrease in non-operating expenses. However, operating costs and expenses increased substantially due to commercialization efforts for INCIVEK and ongoing R&D investments. Vertex also entered into a significant collaboration agreement with Alios BioPharma in June 2011, consolidating Alios' financials and adding substantial intangible assets and goodwill to its balance sheet, highlighting Vertex's strategy of expanding its pipeline through acquisitions and collaborations.

Vertex Pharmaceuticals Inc. reported a net loss of $176.1 million for the first quarter of 2011, an increase from $165.3 million in the same period of the previous year. This widening loss was driven by a significant increase in R&D and SG&A expenses, largely in preparation for the potential launch of its hepatitis C drug, telaprevir. Despite the increased expenses and net loss, total revenues surged by 228% to $73.7 million, primarily due to a $50 million milestone payment from Janssen Pharmaceutica for telaprevir's marketing authorization application acceptance in Europe. The company's cash, cash equivalents, and marketable securities stood at $823.5 million as of March 31, 2011. While this represents a decrease from the prior quarter, management believes it is sufficient to fund operations for at least the next twelve months. Vertex is on track for a potential US launch of telaprevir in mid-2011, contingent on FDA approval, which has an anticipated decision date of May 23, 2011. Additionally, positive Phase 3 results for the cystic fibrosis drug candidate VX-770 were announced, with an NDA submission expected in the second half of 2011. Investors should closely monitor the FDA's decision on telaprevir and the progress of VX-770 as key drivers of future financial performance.

Vertex Pharmaceuticals Inc. reported a net loss of $208.96 million for the third quarter of 2010, an increase from the $149.57 million loss in the same quarter of the previous year. This widened loss was primarily driven by increased operating expenses, particularly in research and development and sales, general, and administrative functions, as the company gears up for the potential commercial launch of its Hepatitis C drug candidate, telaprevir. Total revenues for the quarter slightly decreased to $23.8 million from $24.96 million year-over-year, impacted by lower collaborative revenues from the Janssen collaboration. Despite the increased net loss, the company made significant progress in its clinical programs. Positive Phase 3 data for telaprevir were reported from the ADVANCE, ILLUMINATE, and REALIZE trials, supporting its planned New Drug Application (NDA) submission to the FDA in the fourth quarter of 2010. The company also advanced its cystic fibrosis drug candidate, VX-770, with a registration program expected to yield final data in the first half of 2011. Vertex Pharmaceuticals ended the quarter with $1.2 billion in cash, cash equivalents, and marketable securities, providing sufficient liquidity for at least the next twelve months.

Vertex Pharmaceuticals Inc. (VRTX) reported its financial results for the quarter ending June 30, 2010. The company experienced a significant increase in total revenues, driven by strong growth in collaborative revenues, largely due to an amendment with Mitsubishi Tanabe Pharma Corporation and ongoing reimbursements from Janssen Pharmaceutica, N.V. for the development of telaprevir. Despite the revenue growth, Vertex continued to incur substantial net losses. This was primarily attributed to significant investments in research and development, particularly for telaprevir and VX-770 (cystic fibrosis program), and increasing sales, general, and administrative expenses in preparation for potential product launches. The company's cash, cash equivalents, and marketable securities saw a decrease, reflecting these operational expenditures. Vertex is advancing its lead drug candidate, telaprevir, through its registration program with an expected NDA submission in the second half of 2010 and potential US launch in 2011. The company anticipates needing to raise additional capital to fund its ongoing development and commercialization efforts.